Teleflex Inc. (TFX) Resolves FDA Corporate Warning Letter Issued in October
Tweet
Share
E-mailGet Alerts TFX Hot Sheet
Join SI Premium – FREE
Teleflex Incorporated (NYSE: TFX) has received formal notification that it has successfully resolved all outstanding issues raised by the FDA in a corporate Warning Letter received by its subsidiary, Arrow International.
The Warning Letter was received in October of 2007, and identified FDA’s observations on a variety of Arrow’s quality systems control measures that occurred prior to Teleflex’s acquisition of Arrow.
The Warning Letter was received in October of 2007, and identified FDA’s observations on a variety of Arrow’s quality systems control measures that occurred prior to Teleflex’s acquisition of Arrow.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA grants emergency use for Simparica TRIO to treat screwworm in dogs
- AS Watson signs multi-year deal with NCR Voyix for retail platform
- Bitwise partners with Superstate to explore tokenized ETF shares
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
